Jpmorgan Chase & CO Vanda Pharmaceuticals Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding VNDA
# of Institutions
155Shares Held
44.7MCall Options Held
136KPut Options Held
220K-
Black Rock Inc. New York, NY8.14MShares$39.5 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny4.11MShares$20 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.43MShares$16.6 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA2.15MShares$10.4 Million1.49% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.01MShares$9.77 Million0.0% of portfolio
About Vanda Pharmaceuticals Inc.
- Ticker VNDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,561,500
- Market Cap $274M
- Description
- Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...